<DOC>
	<DOCNO>NCT01375777</DOCNO>
	<brief_summary>The primary objective evaluate effect 12 week subcutaneous evolocumab ( AMG 145 ) every 2 week ( Q2W ) every 4 week ( Q4W ) , compare placebo , percent change baseline LDL-C use monotherapy adult hypercholesterolemia .</brief_summary>
	<brief_title>Monoclonal Antibody Against PCSK9 Reduce Elevated Low-density Lipoprotein Cholesterol ( LDL-C ) Adults Currently Not Receiving Drug Therapy Easing Lipid Levels</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Male female ≥ 18 ≤ 75 year age Low density lipoprotein cholesterol ( LDLC ) ≥ 100 mg/dL &lt; 190 mg/dL Framingham risk score 10 % less Fasting triglyceride &lt; 400 mg/dL History coronary heart disease New York Heart Association ( NYHA ) II IV heart failure Uncontrolled cardiac arrhythmia Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>High cholesterol</keyword>
	<keyword>Proprotein convertase subtilisin/kexin type 9 ( PCSK9 )</keyword>
	<keyword>Treatment high cholesterol</keyword>
	<keyword>Lowering cholesterol</keyword>
	<keyword>Lowering high cholesterol</keyword>
	<keyword>Hypercholesterolemia</keyword>
</DOC>